Therapy for rare bone disease that causes rickets

Targeted drug burosumab helps transform the lives of adults with an inherited condition that leads to low levels of the mineral phosphate in the blood, which is essential for the normal formation of bones, teeth and how other parts of the body work.  This will now be available on the NHS in England to treat XLH (X-linked Hypophosphatemia) which can lead to rickets, an increased risk of fractures due to bone softening, muscle weakness, dental problems including abscesses and loss of teeth, and disability that can affect a person’s work life.